IFN-β modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in the SJL mouse

Journal of Neuroimmunology

Volumn 100, Issue 1-2, 1999, Pages 190-196

  Luca, Mariken E ^a   Visser, Lizette ^a   J Lucas, Cornelis ^a   Nagelkerken, Lex ^a  

^a TNO   (Netherlands)

Author keywords

EAE; Interferon ; Multiple sclerosis; Murine

Indexed keywords

BETA INTERFERON; CYTOKINE; INTERLEUKIN 10;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERFERON-BETA; INTERLEUKIN-10; LYMPHOCYTES; MICE; MICE, INBRED STRAINS; PERTUSSIS TOXIN; RECOMBINANT PROTEINS; TH2 CELLS; TIME FACTORS; VIRULENCE FACTORS, BORDETELLA;

EID: 0033397488     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00198-8     Document Type: Article

References (26)

1. Comabella M., Balashov K., Issazadeh S., Smith D., Weiner H.L., Khoury S.J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102:1998;671-678.
2. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J., Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2499-2504.
3. Guillemard E., Geniteau-Legendre M., Kergot R., Lemaire G., Petit J.F., Labarre C., Quero A.M. Role of trehalose dimycolate-induced interferon-alpha/beta in the restriction of encephalomyocarditis virus growth in vivo and in peritoneal macrophage cultures. Antiviral Res. 28:1995;175-189.
4. Heremans H., Dillen C., Groenen M., Martens E., Billiau A. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur. J. Immunol. 26:1996;2393-2398.
5. Inaoki M., Sato S., Weintraub B.C., Goodnow C.C., Tedder T.F. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J. Exp. Med. 186:1997;1923-1931.
6. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann. Neurol. 39:1996;285-294.
7. Karasuyama H., Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:1988;97-104.
8. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1996;1641-1646.
9. Leonard J.P., Waldburger K.E., Goldman S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:1995;381-386.
10. McRae B.L., Picker L.J., van Seventer G.A. Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur. J. Immunol. 27:1997;2650-2656.
11. Merrill J.E., Kono D.H., Clayton J., Ando D.G., Hinton D.R., Hofman F.M. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL. Proc. Natl. Acad. Sci. U.S.A. 89:1992;574-578.
12. Miller S.D., Karpus W.J. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol. Today. 15:1994;356-361.
13. Nagelkerken L., Blauw B., Tielemans M. IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice. Int. Immunol. 9:1997;1243-1251.
14. Rep M.H., Hintzen R.Q., Polman C.H., van Lier R.A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;111-118.
15. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D.H., Gubler U., Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185:1997;825-831.
16. Rudick In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 50:1998;1294-1300.
17. Rudick R.A., Ransohoff R.M., Peppler R., Medendorp S.V., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40:1996;618-627.
18. Ruuls S.R., de Labie M.C.D.C., Weber K.S., Botman C.A.D., Groenestein R.J., Dijkstra C.D., Olsson T., van der Meide P.H. The length of treatment determines whether IFN-β prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol. 157:1996;5721-5731.
19. Segal B.M., Shevach E.M. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184:1996;771-775.
20. Szabo S.J., Dighe A.S., Gubler U., Murphy K.M. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:1997;817-824.
21. van Boxel-Dezaire A.H., Hoff S.C., van Oosten B.W., Verweij C.L., Drager A.M., Ader H.J., van Houwelingen J.C., Barkhof F., Polman C.H., Nagelkerken L. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45:1999;695-703.
22. Vandermeide P.H., Delabie M.C.D.C., Ruuls S.R., Groenestein R.J., Botman C.A.D., Olsson T., Dijkstra C.D. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 84:1998;14-23.
23. Visser J., van Boxel-Dezaire A., Methorst D., Brunt T., Dekloet E.R., Nagelkerken L. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood. 91:1998;4255-4264.
24. Vodjdani G., Coulombel C., Doly J. Structure and characterization of a murine chromosomal fragment containing the interferon beta gene. J. Mol. Biol. 204:1988;221-231.
25. Wee Yong V., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis. Neurology. 51:1998;682-689.
26. Yu M., Nishiyama A., Trapp B.D., Tuohy V.K. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:1996;91-100.